FDA: Avandia To Stay On The Market
July 30, 2007, 7:19 PM
Lately, there's been a controversy brewing over the safety of a medication many people with diabetes take for months now. But an FDA advisory panel has finally taken a stand on the issue.
The medication we're talking about is Avandia, and the current information points to an increased risk of adverse cardiovascular events, including heart failure and cardiovascular death in diabetic patients. Despite these findings, the FDA advisory panel says the risks are not high enough to warrant pulling the drug from the market.
Avandia is the number one diabetes drug in this country taken by one million Americans. But in May, the same doctor whose research got the arthritis drug Vioxx yanked from the market raised a red flag about Avandia. In hearings today in Washington, the FDA advisors were asked to consider pulling the drug from the market or restrict its use in select patients and brand it with prominent warnings.
Andrew von Eschenbach, FDA Commissioner says, "Once we have that data, we'll advise the American people and their physicians with regard to the appropriate use of Avandia."
Late this afternoon, the FDA took action on Avandia, though it says it will probably have some explaining to do about why it downplayed earlier concerns about the drug, but says for now the drug will stay on the market.
© 2007 KELOLAND TV. All Rights Reserved.